This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
The New England TMS clinical team is under the leadership of Keith Ablow, MD, a psychiatrist who is board certified in adult and adolescent psychiatry by the American Board of Psychiatry and Neurology. Dr. Ablow was educated at Brown University, where he obtained his degree in neurosciences, with highest honors, and at the Johns Hopkins School of Medicine, where he obtained his M.D. Doctor Ablow then completed psychiatry training at Tufts/ New England Medical Center. He has been practicing psychiatry for 22 years, has authored 16 books, has appeared on hundreds of national television broadcasts on psychiatry and was, for years, a Washington Post columnist on new topics in psychiatry.
Please fill all the marked fields